{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T09:50:35Z","timestamp":1790416235476,"version":"4.1.0"},"reference-count":94,"publisher":"Informa UK Limited","issue":"10","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2020,10,2]]},"DOI":"10.1080\/13543776.2020.1811852","type":"journal-article","created":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T00:48:52Z","timestamp":1597798132000},"page":"729-742","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":35,"title":["GPR120 agonists for the treatment of diabetes: a patent review (2014 present)"],"prefix":"10.1080","volume":"30","author":[{"given":"Xuqing","family":"Zhang","sequence":"first","affiliation":[{"name":"Discovery Chemistry, Janssen Research and Development, Spring House, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Macielag","sequence":"additional","affiliation":[{"name":"Discovery Chemistry, Janssen Research and Development, Spring House, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,8,30]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-0442"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.05.064"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.00902"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/2042018810381066"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCO.0b013e32834f4598"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.2174\/09298673113209990168"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2011.00112"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2006.03.011"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2009.07.020"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/164_2016_52"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1168"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.07.041"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2013.11.021"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2009.01114.x"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature10798"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2007.01.028"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S53892"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1248\/yakushi.12-00278-2"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.4155\/fmc.15.75"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1254\/fpj.146.296"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.2174\/1573399811666150302112421"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.4155\/ppa.15.33"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.2013.842977"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2011.04.004"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-009-0425-9"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.110.066324"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0706770"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2012.02052.x"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm800970b"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2014.05.012"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm300215x"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M114.561449"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201601248R"},{"key":"e_1_3_4_36_1","unstructured":"IRM LLC. Compounds and methods for modulating G-protein coupled receptors. WO103501; 2008"},{"key":"e_1_3_4_37_1","unstructured":"IRM LLC. Thiazole derivatives as modulators of G-protein coupled receptors. WO103500; 2008"},{"key":"e_1_3_4_38_1","unstructured":"IRM LLC. Compounds and methods for modulating G-protein coupled receptors. WO008831; 2010"},{"key":"e_1_3_4_39_1","unstructured":"IRM LLC. Compounds and methods for modulating G-protein coupled receptors. WO121570; 2008"},{"key":"e_1_3_4_40_1","unstructured":"Metabolex Inc. GPR120 receptor agonists and uses thereof. WO080537; 2010"},{"key":"e_1_3_4_41_1","unstructured":"Metabolex Inc. GPR120 receptor agonists and uses thereof. WO159297; 2011"},{"key":"e_1_3_4_42_1","unstructured":"Metabolex Inc. Aryl GPR120 receptor agonists and uses thereof. WO048207; 2010"},{"key":"e_1_3_4_43_1","unstructured":"Kindex Therapeutics LLC. cis 3 4-dihydroxy \u22122-(3-methylbutanoyl) \u22125-(\u22123-methylbutyl) \u22124-(4-methylpentanoyl)cyclopent-2-en-1-one derivatives substantially enantiomerically pure compositions and methods. WO058649; 2012"},{"key":"e_1_3_4_44_1","unstructured":"Pharma Frontier Co. Ltd. Novel long chain fatty acid derivative compound and G protein coupled receptor agonist containing the compound as active ingredient. WO038204; 2009"},{"key":"e_1_3_4_45_1","unstructured":"Banyu Pharmaceutical Co. Ltd. Novel isoindolin-1-one derivative. WO104195; 2010"},{"key":"e_1_3_4_46_1","unstructured":"Banyu Pharmaceutical Co. Ltd. Novel phenyl-isoxazol-3-ol derivative. US0130559; 2010"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2017.06.028"},{"key":"e_1_3_4_48_1","unstructured":"Janssen Pharmaceutica NV Preparation of GPR120 agonists for the treatment of type II diabetes. US 20140275179 A1; 2014"},{"key":"e_1_3_4_49_1","unstructured":"Janssen Pharmaceutica NV Preparation of isothiazole derivatives as GPR120 agonists for the treatment of type II diabetes. US 9067898 B1; 2015"},{"key":"e_1_3_4_50_1","unstructured":"Janssen Pharmaceutica NV Preparation of isothiazole derivatives as GPR120 agonists for the treatment of type II diabetes. WO 2015134039 A1; 2015"},{"key":"e_1_3_4_51_1","unstructured":"Janssen Pharmaceutica NV Preparation of bicyclic pyrrole derivatives as GPR120 agonists. US 20140275182 A1; 2014"},{"key":"e_1_3_4_52_1","unstructured":"Janssen Pharmaceutica NV Preparation of bicyclic pyrrole derivatives as GPR120 agonists. US 8912227 B1; 2014"},{"key":"e_1_3_4_53_1","unstructured":"Janssen Pharmaceutica NV Preparation of bicyclic pyrrole derivatives as GPR120 agonists. WO 2015134038 A1; 2015"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.7b00233"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2018.02.013"},{"key":"e_1_3_4_56_1","unstructured":"Janssen Pharmaceutica NV Cycloalkenyl derivatives useful as agonists of the GPR120 and\/or GPR40 receptors and their preparation. WO 2019171277 A1; 2019"},{"key":"e_1_3_4_57_1","unstructured":"Janssen Pharmaceutica NV Heterocycloalkenyl derivatives useful as agonists of the GPR120 and\/or GPR40 receptors and their preparation. WO 2019171278 A1; 2019"},{"key":"e_1_3_4_58_1","unstructured":"Janssen Pharmaceutica NVN Preparation of benzo-fused heterocyclic compounds as agonists of GPR120. US 20140275172 A1; 2010"},{"key":"e_1_3_4_59_1","unstructured":"Merck Sharp & Dohme Corp. Preparation of substituted spiropiperidinyl compounds useful as GPR120 agonists. WO 2014059232 A2; 2014"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.6b00360"},{"key":"e_1_3_4_61_1","unstructured":"Merck Sharp & Dohme Corp. Substituted tetrahydroisoquinoline compounds useful as GPR120 agonists and their preparation. WO 2017205193 A1; 2017"},{"key":"e_1_3_4_62_1","unstructured":"Merck Sharp & Dohme Corp. Substituted tetrahydroisoquinoline compounds useful as GPR120 agonists and their preparation. WO 2017201683 A1; 2017"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2016.10.054"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.6b00394"},{"key":"e_1_3_4_65_1","unstructured":"Merck Sharp & Dohme Corp. Hydroxy isoxazole compounds used as GPR120 agonists and their preparation. WO 2018107415 A1; 2018"},{"key":"e_1_3_4_66_1","unstructured":"Merck Sharp & Dohme Corp. Hydroxy isoxazole compounds used as GPR120 agonists and their preparation. WO 2018111734 A; 2018"},{"key":"e_1_3_4_67_1","unstructured":"Bristol-Myers Squibb Company. Preparation of phenylcycloalkyl and phenylazacycloalkyl carboxylic acid compounds and their analogs as GPR120 modulators useful for treatment of diabetes and related diseases. WO 2016040225 A1; 2016"},{"key":"e_1_3_4_68_1","unstructured":"Bristol-Myers Squibb Company. Preparation of novel cyclopropane carboxylic acid compounds as GPR120 modulators useful for treatment of diabetes and related diseases. WO 2016040222 A1; 2016"},{"key":"e_1_3_4_69_1","unstructured":"Bristol-Myers Squibb Company. Preparation of cyclobutanes containing carboxylic acid as GPR120 modulators useful for treatment of diabetes and related diseases. WO 2016040223 A1; 2016"},{"key":"e_1_3_4_70_1","unstructured":"Bristol-Myers Squibb Company. Preparation of bicycloheptane acid derivatives for use as GPR120 modulators. WO 2014159794 A2; 2014"},{"key":"e_1_3_4_71_1","unstructured":"Bristol-Myers Squibb Company. Preparation of bicyclo[2.2.2]octane derivatives as GPR120 modulators useful for treatment of diabetes and other diseases. WO 2014159802 A1; 2014"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2016.37"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.113.087783"},{"key":"e_1_3_4_74_1","unstructured":"Piramal Enterprises Limited. Preparation of carboxylic acid derivatives for use as GPR120 agonists. WO 2015125085 A1; 2015"},{"key":"e_1_3_4_75_1","unstructured":"Piramal Enterprises Limited. Preparation of thiazole and thiophene derivatives containing carbon-carbon linker as gpr120 agonists for disease therapy. WO 2016125182 A1; 2016"},{"key":"e_1_3_4_76_1","unstructured":"Piramal Enterprises Limited. Preparation of phenyl alkanoic acid derivatives for use as GPR120 agonists. WO 2016012965 A2; 2016"},{"key":"e_1_3_4_77_1","unstructured":"Piramal Enterprises Limited. Preparation of fused heterocyclic compounds as GPR120 agonists. WO 2016038540 A1; 2016"},{"key":"e_1_3_4_78_1","unstructured":"Caldan Therapeutics Limited. Preparation of tetrahydroisoquinoline and tetrahydrobenzoazepine derivatives for use as GPR120 modulators. WO 2018172727 A1; 2018"},{"key":"e_1_3_4_79_1","unstructured":"LG Life Sciences Ltd. Preparation of biaryl derivatives as GPR120 agonists. WO 2014209034 A1; 2014"},{"key":"e_1_3_4_80_1","unstructured":"LG Life Sciences Ltd. Preparation of biaryl derivatives as GPR120 agonists. WO 2016105118 A2"},{"key":"e_1_3_4_81_1","unstructured":"LG Life Sciences Ltd. Preparation of thioaryl derivatives as GPR120 agonists. WO 2014069963 A1; 2014"},{"key":"e_1_3_4_82_1","unstructured":"Ajinomoto Co. Preparation of monoterpene and olefin derivatives as novel GPR120 agonists as food additives. JP 2019156833 A; 2019"},{"key":"e_1_3_4_83_1","unstructured":"Dompe Farmaceutici S.p.A. Preparation of N-(hetero)aryl benzenesulfonamides as GPR40 and GPR120 agonists. EP 3281937 A1; 2018"},{"key":"e_1_3_4_84_1","unstructured":"Dompe Farmaceutici S.p.A. Preparation of N-(hetero)aryl benzenesulfonamides as GPR40 and GPR120 agonists. WO 2018029150 A1; 2018"},{"key":"e_1_3_4_85_1","unstructured":"Axxam S.p.A. Preparation of substituted pyrazoles FFA4\/GPR120 receptor agonists. WO 2019175152 A1; 2019"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.6b00685"},{"key":"e_1_3_4_87_1","unstructured":"Daewoong Pharmceutical Co. Ltd. Novel 3 4-dialkoxyphenyl derivatives and use thereof. WO42666; 1998."},{"key":"e_1_3_4_88_1","unstructured":"Daewoong Pharmaceutical Co. Ltd. 3cyclopentyloxy-4-methoxyphenylisothiazolinone derivatives and use thereof. WO081447; 2002"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2017.01.034"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2018.06.047"},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2017.06.006"},{"key":"e_1_3_4_92_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2011.00112"},{"key":"e_1_3_4_93_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.111.077388"},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.4155\/fmc.15.160"},{"key":"e_1_3_4_95_1","doi-asserted-by":"publisher","DOI":"10.3390\/nu8060329"},{"key":"e_1_3_4_96_1","doi-asserted-by":"publisher","DOI":"10.1007\/164_2016_45"}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2020.1811852","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T05:03:08Z","timestamp":1735794188000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543776.2020.1811852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,30]]},"references-count":94,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10,2]]}},"alternative-id":["10.1080\/13543776.2020.1811852"],"URL":"https:\/\/doi.org\/10.1080\/13543776.2020.1811852","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"value":"1354-3776","type":"print"},{"value":"1744-7674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,30]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-06-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}